DSpace
 

KNUSTSpace >
Research Articles >
College of Health Sciences >

Please use this identifier to cite or link to this item: http://hdl.handle.net/123456789/13534

Title: Aim: This study assesses the effects of HAART on complete blood count parameters among HIV infected participants. Study Design: Case control study. Place and Methods: This study was conducted in Tamale, Ghana from August, 2016 to December, 2017. Methodology: A total of 300 HIV infected participants with ages ranging from 19–79 years, administered with HAART for at least 6 months were recruited. Pre-HAART administratio
Authors: Bani, Simon Bannison
Obirikorang, Christian
Danquah, Kwabena O.
Owiredu, William K. B. A.
Quaye, Lawrence
Sakyi, Samuel Asamoah
Adams, Yussif
Dapare, Peter Paul M.
Banyeh, Moses
Gandau, Barnabas B. N.
Keywords: Highly active antiretroviral therapy
HIV infection
LFT
RFT
HIVAN
Issue Date: 2020
Publisher: International STD Research & Reviews
Citation: International STD Research & Reviews 9(2): 8-16, 2020; Article no.ISRR.59518 ISSN: 2347-5196, NLM ID: 101666147
Abstract: Methodology: A total of 300 HIV infected participants with ages ranging from 19 to 79 years who have been administered with HAART for at least 6 months were recruited. Pre-HAART administration (baseline) demographic and clinical information, with initial liver and renal function test results were retrieved from the medical records of the participants present at the ART center. Post HAART administration blood sample (5 mLs) was taken from each participant into a gel separated vacutainer tube, allowed to clot and spun at 3000 rpm for 3 minutes to produce serum. The product (serum) was used for liver and renal function test analysis using a fully automated chemistry analyser (Vital Scientific Selectra Flexor XL). Results: Of the study population, 72% were administered with AZT/3TC/EFV, 13% with AZT/3TC/NVP, 6.7% with TDF/3TC/LPV/r and TDF/3TC/NVP, 1% with AZT/3TC/EFV while 0.7% were administered with TDF/FTC/EFV. The following parameters were significantly increased post HAART administration; ALT (25.53 ± 16.90 to 30.87 ± 19.28 U/L), ALP (163.7 ± 141.0 to 215.2 ± 143.4 U/L), GGT (37.27 ± 25.21 to 53.19 ± 41.71 U/L), Total protein (73.97 ± 17.08 to 82.31 ± 11.62 g/L), Albumin (38.02 ± 9.331 to 41.01 ± 7.471 g/L), Globulin 38.02 ± 15.71 to 42.79 ± 25.20 (g/L). There were however significant reductions in Total bilirubin (12.13 ± 10.85 to 9.434 ± 4.560 μmol/L), Direct bilirubin (6.616 ± 5.770 to 4.184 ± 2.806 μmol/L), (Creatinine 73.19 ± 36.13 to 63.14 ± 27.14 μmol/L) and Urea (3.515 ± 2.552 to 3.011±1.274 mmol/L). Conclusion: HAART improves renal function, induces elevation in liver enzymes, stimulates the production of plasma proteins and reduces serum bilirubin concentration.
Description: An article published in International STD Research & Reviews 9(2): 8-16, 2020; Article no.ISRR.59518 ISSN: 2347-5196, NLM ID: 101666147
URI: http://hdl.handle.net/123456789/13534
Appears in Collections:College of Health Sciences

Files in This Item:

File Description SizeFormat
30109-Article Text-56477-1-10-20200815.pdf287.26 kBAdobe PDFView/Open

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

 

Valid XHTML 1.0! DSpace Software Copyright © 2002-2010  Duraspace - Feedback